Kumaraguru Raja
Stock Analyst at Brookline Capital
(n/a)
# 4,875
Out of 4,876 analysts
15
Total ratings
7.69%
Success rate
-50.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kumaraguru Raja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PALI Palisade Bio | Maintains: Buy | $16 | $0.72 | +2,116.37% | 2 | May 13, 2025 | |
| QNCX Quince Therapeutics | Initiates: Buy | $9 | $1.43 | +529.06% | 1 | Dec 18, 2024 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $8 | $1.85 | +332.53% | 1 | Jun 7, 2024 | |
| FBRX Forte Biosciences | Initiates: Buy | $100 | $11.70 | +754.70% | 2 | May 30, 2024 | |
| OTLK Outlook Therapeutics | Downgrades: Hold | n/a | $1.71 | - | 1 | Aug 30, 2023 | |
| ADIL Adial Pharmaceuticals | Reiterates: Buy | $150 | $0.36 | +41,566.67% | 2 | Jul 11, 2023 | |
| GNTA Genenta Science | Assumes: Buy | $15 | $3.10 | +384.65% | 1 | Jun 29, 2023 | |
| RAIN Rain Enhancement Technologies Holdco | Reinstates: Buy | $21 | $3.21 | +554.21% | 1 | Jan 31, 2023 | |
| MNPR Monopar Therapeutics | Reinstates: Buy | $90 | $33.99 | +164.78% | 1 | Dec 9, 2022 | |
| VERU Veru Inc. | Maintains: Buy | $29 → $31 | $0.64 | +4,752.85% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,360 | $0.60 | +555,731.27% | 1 | Sep 21, 2021 |
Palisade Bio
May 13, 2025
Maintains: Buy
Price Target: $16
Current: $0.72
Upside: +2,116.37%
Quince Therapeutics
Dec 18, 2024
Initiates: Buy
Price Target: $9
Current: $1.43
Upside: +529.06%
SAB Biotherapeutics
Jun 7, 2024
Initiates: Buy
Price Target: $8
Current: $1.85
Upside: +332.53%
Forte Biosciences
May 30, 2024
Initiates: Buy
Price Target: $100
Current: $11.70
Upside: +754.70%
Outlook Therapeutics
Aug 30, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.71
Upside: -
Adial Pharmaceuticals
Jul 11, 2023
Reiterates: Buy
Price Target: $150
Current: $0.36
Upside: +41,566.67%
Genenta Science
Jun 29, 2023
Assumes: Buy
Price Target: $15
Current: $3.10
Upside: +384.65%
Rain Enhancement Technologies Holdco
Jan 31, 2023
Reinstates: Buy
Price Target: $21
Current: $3.21
Upside: +554.21%
Monopar Therapeutics
Dec 9, 2022
Reinstates: Buy
Price Target: $90
Current: $33.99
Upside: +164.78%
Veru Inc.
May 18, 2022
Maintains: Buy
Price Target: $29 → $31
Current: $0.64
Upside: +4,752.85%
Sep 21, 2021
Initiates: Buy
Price Target: $3,360
Current: $0.60
Upside: +555,731.27%